Neurology Minute

In the second part of this two-part series, Dr. Jeff Ratliff and Dr. Calum Hamilton discuss the clinical criteria that listeners should look out for, indicating a subtype of mild cognitive impairment known as DLB, which could potentially progress into a full dementia with Lewy body phenotype. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209499  

In part one of this two-part series, Dr. Gregg Day and Dr. Sebastian Palmqvist discuss the top-line findings from the study exploring the diagnostic performance of blood biomarkers for Alzheimer disease in clinical cohorts. Show reference: https://jamanetwork.com/journals/jama/fullarticle/2821669   

In this riveting discussion, Dr. Calium, a knowledgeable expert on MCI and dementia risk, joins Dr. Jeff Ratliff, an experienced practitioner in neurodegenerative diseases. They delve into the progression rates of Mild Cognitive Impairment (MCI) toward dementia in patients with Lewy Bodies and Alzheimer's Disease. Alarming statistics emerge, highlighting the critical need for further research and understanding of these conditions. Listeners gain valuable insights into patient outcomes at three and five-year benchmarks.

Dr. Jeff Ratliff, a medical expert in neurology, discusses the groundbreaking FDA approval of Crexant, a new extended-release medication for Parkinson's disease. He delves into its potential to improve motor function and shares insights from the RISE PD trial. The conversation also covers the formulation of the drug and its implications for clinical practice, offering hope for those affected by this challenging condition.

Dr. Jeff Ratliff, a leading expert in neurology, dives into groundbreaking research on deep brain stimulation for Parkinson's disease. He unpacks the advancements in adaptive deep brain stimulation, which tailors treatment using real-time neurophysiological data. This innovative approach promises improved motor symptom management, offering hope for more personalized therapy. Ratliff's insights reveal the potential of adaptive DBS to outperform conventional stimulation methods, paving the way for a new era in Parkinson's disease treatment.

Dr. Tesha Monteith talks about the efficacy of atogepant for the preventive treatment of chronic migraine in participants with and without acute medication overuse. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209584   

Dr. Stacey Clardy and Dr. Nicola de Souza discuss how to improve care in the clinic for these veterans and military service members. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209417

In the first installment of this two-part series, Dr. Jeff Ratliff and Dr. Daniel Weintraub discuss the risks associated with the development of dementia in patients diagnosed with Parkinson disease. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209699 

Dr. Jeff Ratliff, a clinical expert in dopaminergic imaging, joins Dr. Eduardo De Pablo-Fernández, a specialist in clinical interpretations, to discuss critical insights into the limitations of DAT imaging in diagnosing Parkinsonism. They caution against over-reliance on imaging, highlighting potential pitfalls in cases like corticobasal syndrome and progressive supranuclear palsy. The conversation emphasizes the need for careful consideration in differential diagnosis to avoid misleading interpretations.

Dr. Tesha Monteith, an expert on long COVID, delves into its defining characteristics and impact on neurology. She explains that symptoms can arise after any COVID-19 infection, even asymptomatic cases. The discussion highlights the profound effects on emotional health and daily functionality, underscoring the urgency for neurologists to stay abreast of evolving research. Monteith's insights illuminate the ongoing challenges faced by many individuals grappling with long COVID.